Kailera Therapeutics, Inc. (KLRA)
16.23
+0.49
(+3.11%)
USD |
NASDAQ |
Sep 04, 16:00
16.24
+0.01
(+0.06%)
Pre-Market: 20:00
Kailera Therapeutics Research and Development Expense (Quarterly) : 101.06M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 101.06M |
| March 31, 2026 | 70.87M |
| Date | Value |
|---|---|
| June 30, 2025 | 19.52M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Moderna, Inc. | 588.00M |
| Revolution Medicines, Inc. | 392.47M |
| Sana Biotechnology, Inc. | 36.08M |
| Parabilis Medicines, Inc. | 39.38M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |